OptiBiotix Health PLC
Solid Progress Overshadowed
By Alex Langton | 12 May 2025
Mike, Elric, and I are financially interested in SkinBioTherapeutics and OptiBiotix Health.
OptiBiotix Health finds itself at a critical juncture. While commercial developments in key territories like India, the United States, and Australia appear promising, corporate governance failures, questionable communication practices, and mounting shareholder unrest threaten to overshadow the operational progress. I feel I must reflect the perspective of a long-standing investors who approach Father with probing questions and seeking opinions. Despite continuing belief in the company's scientific potential, I feel compelled to raise urgent concerns over boardroom integrity, regulatory compliance, and a pattern of strategic misjudgements—including actions that may have unjustly impacted its former subsidiary, SkinBioTherapeutics, which frankly, defy all reasonable logic.
As a long-standing investor in OptiBiotix, I approach each genuine disappointment and concern not merely as a stakeholder but as someone who believes deeply in the promise of this pioneering microbiome business. My intention is not to disparage, but to highlight, with as much respect and fairness as possible, a series of events and behaviours that now imperil shareholder confidence and corporate integrity, which is being gaining momentum with Tom Winnifriths’ call for board changed, we cannot ignore, lest we fail in our duty to you however uncomfortable this maybe for CEO Stephen O’Hara, with whom we try to work with.